Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALB | P02768 | 11/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14682786 | 0.89 | CA2 (0.37) | ALBFOLH1CA2CA9SMN1; SMN2 | |
| SCHEMBL18145414 | 0.81 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL22712960 | 0.81 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL18145412 | 0.81 | FOLH1 (0.61) | FOLH1 | |
| SCHEMBL13448062 | 0.81 | FOLH1 (0.39) | ALBFOLH1NOD1 | |
| SCHEMBL16446180 | 0.81 | FOLH1 (0.39) | ALBFOLH1NOD1 | |
| SCHEMBL14674508 | 0.80 | ALDH1A1 (0.46) | ALBFOLH1MEN1KMT2A | |
| SCHEMBL15625939 | 0.80 | ALDH1A1 (0.46) | ALBFOLH1MEN1KMT2A | |
| SCHEMBL22691090 | 0.80 | OTC (0.52) | CA2CA9NOD1MEN1KMT2A | |
| SCHEMBL13464207 | 0.80 | OTC (0.52) | CA2CA9NOD1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293206-B2 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | MKI67, CD47, CD68 | ALB 237/4885FOLH1 12/4885CA2 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.